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regions involved in (visceral) nociception (brainstem, insula, 
anterior cingulate cortex) as well as in the homeostatic and 
hedonic regulation of food intake [hypothalamus, (ventral) 
striatum] (p < 0.05 corrected for multiple testing, region of 
interest analysis), which persisted after a follow-up period of 
36 ± 9.6 months.  Conclusions: Although these findings need 
replication in larger samples, they suggest that the abnormal 
brain activity in several of these regions, previously demon-
strated in FD, may be due to a sustained endocannabinoid 
system dysfunction, identifying it as a potential novel target 
for treatment and warranting further studies to elucidate 
whether it is also a feature of other FGIDs or FSSs. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Functional dyspepsia (FD) is the most prevalent func-
tional gastrointestinal disorder (FGID) together with the 
irritable bowel syndrome (IBS). Dyspeptic symptoms af-
fect up to 20% of the general population, and 70% of these 
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 Abstract 
 Background: Functional dyspepsia (FD) is a prevalent func-
tional gastrointestinal disorder (FGID) defined by chronic 
epigastric symptoms in the absence of organic abnormali-
ties likely to explain them. Comorbidity with mood and anx-
iety disorders as well as with other FGIDs and functional so-
matic syndrome (FSS) is high. FD is characterized by abnor-
mal regional cerebral activity in cognitive/affective pain 
modulatory circuits, but it is unknown which neurotransmit-
ter systems are involved. The authors aimed to assess and 
compare in vivo cerebral cannabinoid-1 (CB 1 ) receptor avail-
ability between FD patients and age-, gender- and BMI-
matched healthy controls (HC).  Methods: Twelve FD pa-
tients and 12 matched HC were investigated using positron 
emission tomography (PET) with the CB 1 receptor radioli-
gand [ 18 F]MK-9470. Nine of the patients received a second 
PET scan after a naturalistic follow-up period of 36 ± 9.6 
months (range: 25.2–50.4 months).  Results: FD patients had 
significantly higher CB 1 receptor availability in the cerebral 
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symptoms remain ‘medically unexplained’  [1] . FD is cur-
rently defined by the Rome III diagnostic criteria as ‘the 
presence of chronic symptoms thought to originate in the 
gastroduodenal region in the absence of underlying struc-
tural or metabolic disease that could explain the symp-
toms’  [2] . The cardinal dyspeptic symptoms are epigastric 
pain and burning, postprandial fullness and early satia-
tion, which are often associated with unintentional and 
unexplained weight loss  [3–8] . FD leads to excess diag-
nostic investigations, significant work absenteeism, im-
paired health-related quality of life and high prevalence 
of over-the-counter medication use, all contributing to 
high health care utilization costs, estimated at USD 18.4 
billion in the USA in 2009  [7, 9] . Psychiatric comorbidity 
in FD, as in other FGIDs, is high, particularly with mood, 
anxiety and, to a lesser extent, somatization disorder, al-
though the latter may be driven by the restrictive nature 
of the diagnostic criteria in the Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (DSM-IV)  [10, 
11] . In the general medical literature, FGIDs are consid-
ered to be part of the spectrum of functional somatic syn-
dromes (FSS), including fibromyalgia (FM) and chronic 
fatigue syndrome (CFS), as these syndromes frequently 
overlap  [12, 13] and share other features such as high co-
morbidity with mood and anxiety disorders  [14] . More 
information on how this relates to psychiatric terminol-
ogy and classification (‘somatoform disorders’ in DSM-
IV, ‘somatic symptom disorders’ in DSM-V) is given in 
the online supplementary text (for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000375454).
 Although intensively investigated in the past 2 decades, 
the pathophysiology of FD remains unclear, and treatment 
options are limited. FD symptoms have been attributed to 
complex interactions between peripheral and central 
mechanisms, including gastric sensorimotor dysfunction, 
such as delayed gastric emptying, impaired accommoda-
tion or visceral hypersensitivity (quantified as lower thresh-
olds to gastric balloon distension), (neuro)immune mech-
anisms and psychosocial processes, although the exact 
mechanisms remain unclear  [3, 4, 11, 15–18] . The ‘brain-
gut axis’ (BGA) is the complex, bidirectional neurohumor-
al communication system between the gastrointestinal 
tract and the brain; it plays a key role in the regulation of 
appetite and food intake as well as in visceral nociception. 
Dysfunction of the brain-gut axis has emerged as a gener-
ally accepted model to explain the cardinal symptoms of 
FD in general and the role of central and/or psychological 
processes in particular  [11, 19] . In an H 2 15 O positron emis-
sion tomography (PET) study, we found differences in 
brain activity in regions involved in the processing and 
modulation of (visceral) pain between FD patients and 
healthy controls (HC), during rest and (anticipated) pain-
ful gastric distension  [20] . Our results were confirmed by 
a recent fluorodeoxyglucose PET study, in which the cere-
bral glucose metabolism was compared between FD pa-
tients and HC during rest. FD patients showed a higher 
glucose metabolism in regions involved in the processing 
of visceral homeostatic-afferent information (‘homeostat-
ic-afferent’ network: thalamus, anterior midcingulate cor-
tex, posterior insula) as well as modulation of these vis-
ceral sensory inputs (‘emotional-arousal’ and ‘cortical 
modulatory’ networks: amygdala, pregenual and subgenu-
al anterior cingulate cortex, dorsolateral, ventrolateral and 
ventromedial prefrontal cortex). Further, differences were 
found in areas involved in (food) reward processing (the 
striatum)  [21] . These findings are generally in line with 
findings in other FGIDs/FSSs, including IBS  [22] , FM  [23] 
and somatoform disorders  [24, 25] , pointing towards a 
dysfunction of central and descending pain modulatory 
pathways as a potential common mechanism  [23, 26–28] . 
However, the neurotransmitter system(s) underlying this 
abnormal resting brain activity in FD remain(s) to be elu-
cidated; this would be a crucial next step to identify poten-
tial novel treatment targets. 
 The endocannabinoid system (ECS) is a neuromodu-
latory system that includes a family of naturally occurring 
arachidonate-based lipids, the endocannabinoids [in-
cluding anandamide (N-arachidonoylethanolamide) and 
2-arachidonoylglycerol], their G protein-coupled recep-
tors [cannabinoid-1 (CB 1 ) and cannabinoid-2 receptors], 
enzymes involved in endocannabinoid biosynthesis and 
catabolism, and proteins regulating the uptake and trans-
port of endocannabinoids  [29, 30] . The CB 1 receptor is 
one of the most abundant neuromodulatory receptors in 
the central nervous system, where it is mainly expressed 
presynaptically  [31] . The ECS plays an important role in 
the transmission, processing and modulation of pain sig-
nals at several levels along the pain pathways, from pe-
ripheral sensory nerve endings via the dorsal horn of the 
spinal cord to (sub)cortical regions of the ‘pain neuroma-
trix’ in the brain  [32] . More specifically, the ECS is cru-
cially involved in the central and descending pain modu-
latory system, including the periaqueductal gray (PAG) 
and the rostral ventromedial medulla  [32, 33] . Further, 
CB 1 receptors are abundant in brain regions involved in 
the homeostatic and hedonic control of food intake such 
as the nucleus of the solitary tract, the hypothalamus, 
amygdala and striatum  [34, 35] . Increased CB 1 receptor 
availability has been found in (sub)cortical brain areas in 
patients with bulimia and anorexia nervosa using PET 
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and the selective  18 F-labelled radiotracer [ 18 F]MK-9470 
 [36] . Based on this body of evidence, most of which comes 
from animal research, the ECS is a prime candidate neu-
rotransmitter system to explain the differences in region-
al brain activity between FD patients and HC. However, 
data on cerebral CB 1 receptor availability in FSS/FGID in 
general and in FD in particular are lacking.
 First, we aimed to investigate whether regional cere-
bral CB 1 receptor availability differs between FD patients 
and age-, gender- and BMI-matched HC using PET and 
the CB 1 receptor radiotracer [ 18 F]MK-9470  [37] . We hy-
pothesized differences in CB 1 receptor availability in key 
regions involved in the processing and modulation of vis-
ceral pain as well as in the homeostatic and hedonic regu-
lation of appetite and food intake. Second, we aimed to 
determine whether the (altered) CB 1 receptor availability 
in FD patients is a stable feature of the disorder by rescan-
ning patients after a mean follow-up period of 36 months.
 Methods and Materials 
 Participants 
 Twelve FD patients with unintentional weight loss since the 
onset of symptoms and 12 age-, gender- and BMI-matched HC 
were included in the study. Patient recruitment took place between 
August 2008 and December 2010 at the multidisciplinary neuro-
gastroenterology-liaison psychiatry outpatient clinic of the Uni-
versity Hospital Leuven, a tertiary care referral centre. All FD pa-
tients were diagnosed based on the Rome III criteria  [2] . Prior to 
inclusion, each patient was screened by means of the MINI-Inter-
national Neuropsychiatric Interview performed by a trained psy-
chiatrist (L.V.O.)  [38] . Exclusion criteria were the presence of co-
morbid psychiatric disorders (including eating disorders, sub-
stance-related disorders and somatization disorder) and/or 
somatic disorders (including other FSS except IBS), use of psycho-
tropic medications and/or (recreational) drugs. It should be noted, 
however, that in terms of somatoform disorders, we only excluded 
somatization disorder as defined by DSM-IV. Thus, the overlap of 
FD with DSM-IV’s ‘undifferentiated somatoform disorder’ was 
not explicitly excluded. 
 The severity of dyspeptic symptoms in FD patients was evalu-
ated using the Dyspepsia Symptom Severity (DSS) scale  [39] , quan-
tified as the sum of the intensity of 9 dyspeptic symptoms (discom-
fort, epigastric pain, postprandial fullness, bloating, early satiety, 
nausea, vomiting, epigastric burning and belching) over the past 3 
months, rated on a Likert scale from 0 to 3  [39] . The overall so-
matic symptom severity (‘somatization’) was assessed using the Pa-
tient Health Questionnaire (PHQ-15)  [40] , and thoughts, feelings 
and behaviours related to the somatic symptoms and associated 
health concerns were assessed using the Illness Attitude Scales 
(IAS)  [41] and the Pain Coping and Cognition List (PCCL)  [42] .
 HC were recruited between March 2005 and July 2007 in re-
sponse to advertisements on the departmental homepage and in 
local newspapers and were selected from previous CB 1 PET studies 
 [43, 44] to obtain a sample that was age-, sex- and BMI-matched 
to the patient sample. All controls were asymptomatic, were 
screened for neuropsychiatric and other medical disorders and un-
derwent physical examination and blood and urine testing. Inclu-
sion and exclusion criteria were as described previously  [43] . 
 Each FD patient received a CB 1 PET scan at inclusion (FD1); 9 
of the FD patients underwent a second CB 1 PET scan (FD2) after 
a naturalistic (that is, all treatments were allowed) follow-up of 36 
± 9.6 months (range: 25.2–50.4).
 Details about radiotracer characteristics and preparation, im-
aging procedures (including the acquisition parameters of the 
standard structural magnetic resonance imaging scan used for the 
coregistration of the PET images) and image processing are pro-
vided in the online supplementary text.
 The study was approved by the medical ethics committee of the 
University Hospitals Leuven (ML7928) and was performed ac-
cording to the Declaration of Helsinki. After a complete descrip-
tion of the study to the subjects, written informed consent was 
obtained.
 Data Analysis 
 Whole-brain voxel-based analysis was conducted using SPM8 
(Wellcome Trust Department of Cognitive Neuroscience, Lon-
don, UK). Absolute CB 1 receptor availability differences between 
FD1 and HC and between FD1 and FD2 were assessed using, re-
spectively, independent-sample and paired Student’s t tests at a 
voxel level threshold of T >3.4 (corresponding with p uncorrected 
<0.001), combined with an extent threshold of k E >100 voxels. We 
indicate which clusters survive a more stringent cluster-level 
threshold of p FWE-corrected <0.05.
 In addition to the whole-brain analysis, a region of interest 
(ROI) analysis was performed (details in online suppl. text, list in 
online suppl. table 1) .  The average modified standard uptake value 
(mSUV) within each ROI was determined using PMOD and com-
pared by means of independent-sample and paired t tests for FD1 
versus HC and FD1 versus FD2, respectively, using SAS 9.3 (SAS 
Institute, Cary, N.C., USA). Bootstrapping was used to control the 
familywise error rate associated with multiple testing  [45] .
 The DSS scores and BMI at FD1 and FD2 were compared by 
means of paired t tests; individual dyspeptic symptom scores were 
compared by one-sample t tests with H 0 :  μ 0 = 0 on the percentage 
change between FD1 and FD2. 
 Data are shown as means ± SD; effect sizes are expressed as Co-
hen’s d.
 Results 
 Participant Characteristics at Inclusion 
 Twelve FD patients (11 women; age: 29.8 ± 11.0 years; 
BMI: 18.4 ± 2.5) as well as 12 gender-, age- and BMI-
matched HC (11 women; age: 25.0 ± 13.7 years; BMI: 20.0 
± 1.3) underwent the first scan (FD1). The FD patients 
scored 13.9 ± 3.6 on the DSS and reported a mean weight 
loss since the onset of the symptoms of 11 ± 7.4 kg. Meal-
related symptoms (postprandial fullness: mean ± SD = 2.1 
± 0.3, range = 2–3, median = 2, interquartile range = 2–2; 
early satiation: mean ± SD = 2.0 ± 0.5, range = 1–3, me-
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dian = 2, interquartile range = 2–2) were predominant, 
but epigastric pain was also present in all patients (mean 
± SD = 1.6 ± 0.6, range = 1–3, median = 2, interquartile 
range = 1–2; online suppl. fig. 1). Therefore, FD patients 
fulfilled the Rome III criteria for postprandial distress 
syndrome with overlapping epigastric pain syndrome, 2 
subdivisions of FD proposed in the Rome III criteria  [2] . 
 Detailed information on somatization (including po-
tential comorbidity with DSM-IV somatoform disorders 
as well as DSM-V somatic symptom disorders), health- 
and symptom-related cognitions, feelings and behaviour 
(obtained using the PHQ-15, the IAS and the PCCL) is 
provided in the online supplementary text.
 Table 1.  Regional cerebral CB1 receptor availability in FD patients compared to HC: results of whole-brain, voxel-based statistical para-
metric mapping analysis
Clus-
ter
Cluster level Peak level Local max. MNI 
 coordinates
Anatomical localization BA
pFWE-corrected kE T puncorrected  x y z
1 0.183 431 4.11 0.000 14 –74 30 Right cuneus 7
3.82 0.000 24 –64 16 Right posterior cingulate cortex 31
2 0.009 8,307 4.07 0.000 –42 18 –18 Left superior temporal gyrus/inferior frontal gyrus 38/47
4.05 0.000 –42 –32 12 Left superior temporal gyrus/operculum 1 41
4.05 0.000 8 –16 52 Right supplementary motor area/medial frontal gyrus 6
4.01 0.000 –6 0 68 Left supplementary motor area/medial frontal gyrus 6
4.01 0.000 –36 –8 60 Left precentral gyrus 6
4.00 0.000 6 –8 50 Right supplementary motor area/anterior midcingulate 
cortex
6/24
3.95 0.000 –30 12 –22 Left inferior frontal gyrus/ventrolateral prefrontal cortex 47
3.85 0.000 –40 8 0 Left insula 13
3.80 0.000 10 42 6 Right perigenual anterior cingulate cortex 32
3.79 0.000 –4 34 –12 Left ventromedial prefrontal cortex 11
3.73 0.001 –60 –20 10 Left transverse/superior temporal gyrus 42
3.71 0.001 14 20 38 Right anterior midcingulate cortex 32
3.69 0.001 –2 4 –12 Left subgenual acterior cingulate cortex 25
3.62 0.001 6 8 30 Right anterior midcingulate cortex 24
3.58 0.001 –14 4 –22 Left parahippocampal gyrus/uncus 28/34
3.55 0.001 –2 22 28 Left perigenual anterior cingulate cortex/anterior 
midcingulate cortex
24
3 0.164 593 4.03 0.000 –52 6 28 Left precentral gyrus 44
3.60 0.001 –60 –8 30 Left postcentral gyrus 43
4 0.121 1,128 4.03 0.000 –50 –68 –16 Left inferior occipital gyrus 19
3.77 0.001 –40 –80 –20 Left fusiform gyrus 19
3.54 0.001 –56 –60 16 Left superior/middle temporal gyrus 22/37
5 0.235 142 4.00 0.000 2 –24 0 Right brainstem: midbrain
6 0.235 121 3.99 0.000 14 58 –20 Right superior orbitofrontal cortex/ventromedial 
prefrontal cortex
11
7 0.21 244 3.88 0.000 –26 –84 36 Left midoccipital gyrus 19
8 0.175 492 3.82 0.001 46 14 –18 Right superior temporal gyrus 38
3.66 0.001 46 –6 –2 Right posterior insula 13
9 0.151 726 3.72 0.001 4 –66 –38 Right cerebellum: vermis
 Whole-brain, voxel-based analysis of absolute CB1 receptor availability at a voxel level threshold of T >3.4 (corresponding to 
puncorrected <0.001) and an extent threshold of kE >100 voxels was performed using SPM8. The CB1 receptor availability in FD patients 
and controls was compared using unpaired Student’s t test. Italicized values are significant at an additional cluster level threshold of 
pFWE-corrected <0.05. BA = Brodmann area; FWE = familywise error; kE = cluster size extent; MNI = Montreal Neurological Institute.
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 Evolution of DSS and BMI 
 Nine of the 12 FD patients (8 women; age: 32.9 ± 12.2 
years) underwent a second scan (FD2) after follow-up. The 
evolution of the DSS score and the BMI between FD1 and 
FD2 is summarized in online supplementary figure 2A and 
B ,  respectively. The observed decrease in the DSS score was 
borderline significant (FD1: 13.9 ± 3.6, FD2: 10.0 ± 4.5, p = 
0.056) with a large effect size (Cohen’s d = 0.89), indicating 
an overall improvement in symptoms. As evident from on-
line supplementary figure 2A, most patients reported an im-
provement of their dyspepsia symptoms, with only 2 of the 
9 patients (22.2%) rating their symptoms as worse. Further, 
a borderline significant increase in BMI was found (FD1: 
18.4 ± 2.5, FD2: 20.1 ± 2. p = 0.058) with a medium effect 
size (Cohen’s d = 0.60), indicating a recovery of weight loss. 
Seven of the 9 patients (77.8%) had gained weight at fol-
low-up.
 The results on the evolution of the 9 individual dys-
peptic symptoms are shown in the online supplementary 
text and in online supplementary figure 1.
 CB 1 Receptor Availability in FD versus HC 
 Whole-brain voxel-based analysis showed a signifi-
cantly higher absolute CB 1 receptor availability in FD 
 patients compared to HC with local maxima in the fol-
lowing brain regions: posterior insula, midbrain, ven-
tromedial prefrontal cortex, posterior cingulate cortex, 
precentral and postcentral gyrus, middle and inferior oc-
cipital gyri, superior/middle temporal gyri (including 
 fusiform gyrus), cuneus and cerebellum. One large clus-
ter survived an additional cluster-level threshold of 
p FWE-corrected <0.05 with local maxima in the parahippo-
campal gyrus, rolandic operculum, supplementary motor 
area, ventromedial prefrontal cortex and ventrolateral 
prefrontal cortex, precentral gyrus, insula, subgenual and 
perigenual anterior cingulate cortex and anterior midcin-
gulate cortex. Results are listed in  table 1 and visualized 
in  figure 1 .
 In the FD patient sample, no significant correlation 
between DSS score and CB 1 receptor availability was 
found in any brain region. However, it should be noted 
that this correlation analysis has low power given the 
rather small sample size. Hence, the lack of a significant 
correlation should be interpreted with great caution.
 In keeping with the whole-brain results, the ROI analy-
sis showed a higher regional CB 1 receptor availability in 
FD (range: 19.2–27.7% compared to HC; online suppl. ta-
ble 3 and fig. 2A), with all differences being significant af-
ter correction for multiple testing, with large effect sizes 
(all Cohen’s d >1.0). As results for the left and right hemi-
sphere were very similar for all ROIs, bilateral ROIs were 
used. An additional ROI analysis of the PAG and medulla 
oblongata using SPM8 revealed significant differences in 
CB 1 receptor availability at p FWE-corrected <0.05 in the left 
Insula
X
Y Z
aMCC
pACC
Midbrain
sACC
T values
4.0
3.8
3.6
3.4
 Fig. 1. Regional cerebral CD 1 receptor 
availability in FD patients compared to 
HC: results of whole-brain voxel-based 
analysis. Absolute increase in CB 1 receptor 
availability in FD patients compared to HC 
in transverse, coronal and sagittal sections 
overlaid on a normalized canonical image 
(ch2better template) available in MRIcro 
software. The colour bar represents T 
scores. aMCC = Anterior midcingulate 
cortex; pACC = perigenual anterior cingu-
late cortex; sACC = subgenual anterior cin-
gulate cortex. 
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PAG (local maximum at x = –2, y = –30, z = –8, T = 3.75, 
k E = 100), but not in the medulla. 
 Evolution of CB 1 Receptor Availability in FD 
 Whole-brain voxel-based analysis showed no signifi-
cant differences in CB 1 receptor availability between FD1 
and FD2. The results of the ROI analysis confirmed the 
voxel-based results, as the CB 1 receptor availability did not 
significantly change (all p uncorrected >0.42) in any of the 
ROIs after an average follow-up of 36 ± 9.6 months (online 
suppl. table 4 and fig. 2B). Effect sizes were small for all 
ROIs (Cohen’s d <0.38) (details not shown).
 Figure 3 displays the mean global CB 1 receptor avail-
ability in HC and FD patients at FD1 and FD2.
 Discussion 
 We present the first evidence of sustained central ECS 
dysfunction in FD or indeed in any FGID, FSS or somato-
form disorder/somatic symptom disorder. Compared to 
HC, FD patients had higher CB 1 receptor availability in 
regions involved in (visceral) nociception as well as the 
homeostatic and hedonic regulation of appetite and food 
intake, which was stable over a long naturalistic follow-up 
period of 36 ± 9.6 months. 
 The subjective perception of (visceral) pain is a homeo-
static emotion, resulting from coordinated activity in 3 
distinct yet highly intertwined cerebral networks: the ho-
meostatic-afferent, emotional-arousal and cortical-modu-
latory network  [19] . The first one is primarily involved in 
the processing of (visceral) afferent inputs, whereas the 
other two are primarily pain modulatory networks through 
which cognition and emotion exert their effects on the per-
ception of (visceral) pain  [19, 27] . FD is characterized by 
abnormal neural activity during the anticipation and sub-
sequent processing of painful stimuli in several regions of 
these networks  [20] . More specifically, the altered (de)ac-
tivation pattern in these patients may represent failure of 
these pain modulatory systems  [20] . We found increased 
CB 1 receptor availability in the homeostatic-afferent (pos-
terior insula, anterior midcingulate cortex), cortical-mod-
ulatory (lateral and medial prefronal cortex) and emotion-
al-arousal (amygdala, subgenual anterior cingulate cortex) 
areas. CB 1 receptor availability was also increased in the 
cerebellum, which has an incompletely understood role in 
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 Fig. 2. Regional cerebral CB 1 receptor availability: results of ROI 
analysis.  a FD patients (FD1) versus HC. In a priori ROIs, mean 
mSUVs were calculated and compared using unpaired Student’s t 
test. Bootstrapping was used to correct for multiple testing.
 *   = p bootstrap-corrected <0.05.  b Within the FD patient group: FD1 
versus FD2. In a priori ROIs, mean mSUVs were calculated and 
compared using paired Student’s t test. No significant differences 
were found in any of the ROIs, even without correction for mul-
tiple testing. Data represent means ± SD. vlPFC = Ventrolateral 
prefrontal cortex; dlPFC = dorsolateral prefrontal cortex; 
vmPFC = ventromedial prefrontal cortex; SII = secondary somato-
sensory cortex; AMYG = amygdala; CNC = caudate nucleus;
PUT = putamen; NACC = nucleus accumbens; INS = insula;
sACC = subgenual anterior cingulate cortex; pMCC/PCC = post-
erior midcingulate cortex/posterior cingulate cortex; pACC/
aMCC = perigenual anterior cingulate cortex/anterior midcingu-
late cortex; HYPOTHAL = hypothalamus.  
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nociception  [46] , the parahippocampal gyrus and the cau-
date nucleus, regions associated with cognitive coping 
strategies during the anticipation of noxious stimuli  [47] 
and anxiety-driven pain modulation  [48] . Importantly, 
the PAG also showed increased CB 1 receptor availability. 
This region is a key hub of the descending pathways origi-
nating in central pain modulatory circuits, malfunction of 
which plays an important role in pathophysiology of FSS, 
including FGID  [27, 28] . Taken together, these observa-
tions advocate for a role of endocannabinoid signalling in 
altered (visceral) pain processing and its modulation by 
cognitive and affective factors, thereby contributing to the 
pathogenesis and/or exacerbation of dyspeptic symptoms 
like epigastric pain and discomfort. This warrants studies 
on the involvement of the ECS in other pain-predominant 
FSS, including IBS and FM, or, more broadly, somatoform 
disorders or somatic symptom disorders. As this diagnosis 
is characterized by distressing, often painful symptoms 
and excessive cognitive-affective processes associated with 
them, the dysfunction of cognitive-affective pain modula-
tory circuitry may be an important mechanism, as shown 
in somatoform pain disorder patients  [24] . Based on our 
current findings, the ECS may be a candidate neurotrans-
mitter system involved in this dysfunction.
 Besides its role in (visceral) nociception, the ECS is also 
important in regulating feeding behaviour and energy ho-
meostasis, in addition to its role in (visceral) nociception 
 [32, 34, 35] . Activation of the ECS by exogenous cannabi-
noid agonists increases appetite, especially for sweet and 
fatty foods  [49] . It has been postulated that the orexigenic 
effects of endocannabinoid signalling in the central ner-
vous system are exerted on 2 functional levels: the hypo-
thalamus (homeostatic) and the reward system (hedonic) 
 [49] . The hypothalamus receives and integrates both cen-
tral and peripheral input signalling metabolic state. At the 
level of the reward system, including orbitofrontal cortex, 
amygdala, ventral striatum (nucleus accumbens) and dor-
sal striatum (caudate nucleus and putamen), the ECS 
modulates the motivation to consume food, putatively by 
increasing both appetite (anticipatory reward) and the he-
donic effects of food consumption (consummatory re-
ward)  [34] . These orexigenic actions of the ECS are likely 
mediated by dopamine, as endocannabinoids act as retro-
grade messengers, exerting their modulatory function in 
the ventral tegmental area, where dopamine projections 
to the striatum originate, through modulation of GABA-
ergic and/or glutamatergic synaptic inputs  [50] . We found 
that FD patients show increased CB 1 receptor availability 
in regions involved in both the homeostatic and the he-
donic control of appetite and food intake. Thus, we could 
speculate that dysfunction of the ECS could play a role in 
the disturbed appetite, weight loss and meal-related symp-
toms often observed in these patients. 
 It remains to be elucidated whether elevated CB 1 recep-
tor expression in the central nervous system is primarily 
implicated in abnormal nociception and/or in the dis-
turbed appetite, weight loss and meal-related symptoms, 
which are also important features of FD. However, the two 
possibilities are not mutually exclusive as there is mount-
ing evidence for an interaction between pain and reward 
systems. First, the expectation of pain relief promotes pla-
cebo analgesia, and this relief expectancy can be consid-
ered as reward expectation  [51–53] . Second, several stud-
ies in humans and animals have demonstrated a remark-
able overlap of brain regions implicated in both pain and 
reward processing  [54] . Last, opioidergic and dopaminer-
gic neurotransmission play an important role in both no-
ciception and reward  [55–58] . Taking into account its 
modulatory effect on both these systems, the dysfunction 
of the ECS has the potential to alter both pain perception 
 Fig. 3. Parametric images of global CB 1 receptor availability in HC 
and FD patients at the FD1 and FD2. The colour bar indicates CB 1 
receptor availability expressed as average mSUV of the radioligand 
[ 18 F]MK-9470. 
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and reward processing. Future studies assessing the CB 1 
receptor availability in patient groups which are character-
ized by painful physical symptoms only (e.g. IBS and oth-
er FSS such as FM), dysregulated appetite and weight only 
(e.g. obesity) and/or a variable combination of both (e.g. 
major depression) could clarify whether the ECS changes 
found in the present study primarily play a role in altered 
(visceral) nociception and/or dysregulation of appetite 
and body weight. More specifically, studying CB 1 receptor 
availability in major depression, where loss of appetite and 
body weight is part of the broader phenomenon of anhe-
donia, would teach us whether its role is primarily in emo-
tional regulation in general or in appetite regulation in 
particular. However, using the same CB 1 radiotracer [ 18 F]
MK-9470, Gérard et al.  [36] found significantly elevated 
CB 1 receptor binding in anorexia nervosa patients in com-
parison with age-matched HC, supporting an involvement 
of this system in (disorders of) appetite and food intake 
regulation. Further, the exclusion of comorbid depression 
in our study sample avoids confounding of the present re-
sults in HC versus FD patients by depressive comorbidity.
 In any case, the underlying mechanism for the in-
creased CB 1 receptor availability in FD remains unclear. 
First, increased CB 1 receptor availability could point to a 
compensatory receptor upregulation. The authors of the 
above-mentioned study in eating disorders  [36] inter-
preted the overall increase in CB 1 radiotracer binding as 
an upregulation of CB 1 receptors secondary to the previ-
ously hypothesized (long-term) hypoactivity of the ECS 
in these patients  [59] . Second, increased CB 1 radiotracer 
binding values in FD could be due to a primary increase 
in receptor expression, independent from the level of en-
docannabinoids in the brain  [60] .
 To assess whether the increased cerebral CB 1 receptor 
availability remains stable over time, 9 of the 12 FD pa-
tients underwent a second CB 1 PET scan after a follow-up 
period of on average 36 months. No significant differenc-
es in CB 1 receptor availability between the 2 scan sessions 
could be found in any of the cerebral regions, despite clear 
(but borderline significant in this smaller group) improve-
ments in dyspepsia symptoms and weight loss. Thus, the 
increased CB 1 receptor availability in FD seems to be in-
dependent of fluctuations in dyspeptic symptom levels or 
weight loss, suggesting that the elevated CB 1 receptor 
availability found in FD may reflect a primary (predispos-
ing) feature or vulnerability factor, rather than being sec-
ondary to symptoms or weight loss. A possible way to fur-
ther test this hypothesis would be to administer exoge-
nous CB 1 receptor antagonists or agonists to FD patients 
and subsequently monitor their symptom severity or 
weight loss, but a lack of suitable ligands currently pre-
cludes such study. However, this does not preclude the 
possibility that the differences found are secondary to dis-
ease onset or course (both in terms of dyspeptic symptom 
burden and/or weight loss). Therefore, further studies in 
larger samples are needed. Ideally, one should be able to 
scan the participants prior to and after symptom onset. 
However, such an approach is not feasible in practice. 
Therefore, we believe our approach using a follow-up scan 
is the most preferable and realistic approach.
 This study has a number of limitations which should 
be addressed. First, the strict inclusion criteria, includ-
ing absence of psychotropic drug use and coexisting 
mood, anxiety and somatization disorders, resulted in a 
relatively small sample size. Hence, caution is required 
in interpreting these results, and replication is needed 
before any definite conclusions can be drawn. However, 
the size of our patient sample is comparable to previous 
[ 18 F]MK-9470 radioligand studies  [36, 61] , and a post 
hoc power calculation based on the large effect size for 
all the regions in the ROI analysis (average Cohen’s d = 
1.26) indicates that the study has 84% power. Further, 
the strict inclusion criteria resulted in a relatively homo-
geneous FD sample carefully matched with HC for age, 
gender and BMI, which should be considered a strength. 
However, a sample of this size does not allow to control 
for all possible sources of heterogeneity, including vari-
ability in gastric sensorimotor function, somatization, 
etc. Second, as all patients were recruited at a tertiary 
care centre, our observations do not necessarily apply to 
the less severely affected FD population. Third, inclu-
sion of a second group of HC matched for weight loss 
would have enabled us to evaluate the possible contribu-
tion of weight loss to the observed increase in receptor 
availability in FD. However, it is hardly feasible in prac-
tice to recruit HC with a similar amount of weight loss 
due to, for instance, dieting, within the lower normal 
BMI range. Fourth, since the decision to rescan the FD 
patients was made after the analysis of the PET images 
of the first scan session, the follow-up period was not 
standardized in terms of duration and treatment. This 
explains the considerable range of the follow-up period 
as well as its naturalistic nature. Fifth, as 3 patients de-
clined participation in the second session, we could only 
collect a follow-up scan in 9 of the 12 patients. 
 In summary, this is the first study demonstrating a sig-
nificant increase in cerebral CB 1 receptor availability in 
FD patients compared to matched HC in brain regions 
involved in the regulation of (visceral) pain and the con-
trol of food intake. This increase remained stable over a 
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long naturalistic follow-up period despite improvement 
in symptom levels and recovery of weight loss. This study 
thereby provides the first evidence for an involvement of 
the central ECS in any FGID or FSS. Given the small sam-
ple size, caution is required when interpreting these find-
ings. Additional studies in larger numbers of patients are 
needed to confirm these results. Further research is war-
ranted to determine whether this elevated receptor avail-
ability is primarily implicated in altered gastric nocicep-
tion, dysregulation of food intake, or both, and to eluci-
date the mechanisms underlying this increased receptor 
availability. Moreover, these results warrant further stud-
ies on the ECS as a potential novel target for the pharma-
cological treatment of FD as well as a potentially impor-
tant candidate mechanism in FGID or FSS in general.
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